Survey Shows Americans Think the FDA Regulates the CBD Industry

November 15, 2019 16:00:50

The cannabidiol (CBD) issue is quite a divisive one. The cannabis extract has come from obscurity to an insane level of fame in a surprisingly short time. In 2018, it was the third most searched for item in the US, and the sector is expected to undergo further growth in the coming years.

However, despite CBD’s staggering popularity, it turns out that a large percentage of Americans are unbelievably misinformed about crucial aspects of CBD. A survey by US-based Grocery Manufacturers Association (GMA) found that roughly three-quarters of Americans falsely believe that the U.S. Food and Drug Administration regulates and monitors commercial CBD products.

The October report found that among the 2,056 US adults surveyed, 62% were aware of CBD, 72% of them thought that there was a federal policy in place to regulate commercially sold CBD-infused products. Of the participants who were aware of CBD, 16% were not sure whether or not the products were being regulated.

The unprecedented growth of the CBD industry has resulted in a wide array of sellers, each claiming their CBD product has certain medical benefits. This has led to concerns among health officials as well as retailers’ groups and drug reform advocates who worry that without a robust regulatory structure, there’s no way for consumers to know what’s actually in the products they use.

The National Organization for the Reform of Marijuana Laws (NORML) noted in a press conference that “in many instances, the actual quantities of CBD in the product are far lower than advertised. In other cases, tests revealed the presence of THC or elevated levels of heavy metals and solvents, as well as psychoactive synthetic adulterants in commercial products.”

According to NORML, a lot of these unregulated products are widely and easily accessible, and you can find them in numerous national grocery stores, gas stations, clothing stores, and many thousands of small businesses.

GMA President and CEO Geoff Freeman says the FDA has pledged to give consumers the information they need to make smart choices about CBD products. Still, it is estimated that it could take up to five years to establish Federal CBD regulations. He adds that such a timeline is unacceptable for a market facing such massive growth.

In the meantime, the results from the survey are a clear indication that Americans need to be educated on the growing CBD industry sans federal regulation of CBD-infused products.

This gap in consumer information about CBD products may explain why industry players like Neutra Corp. (OTC: NTRR) and Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) have lots of consumer education materials on all their media outlets.

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published:

Do you have a questions or are you interested in working with CNW? Ask Our Editor

Denver, Colorado
303.498.7722 Office

CBDWire is part of the InvestorBrandNetwork.